• MBX Biosciences outlined a catalyst schedule led by canvuparatide (MBX 2109) Phase 3 initiation in Q3 2026.
• Canvuparatide Phase 2 Avail responder rates shown at 79% at 12 weeks, 63% at 6 months, 57% at 1 year.
• Phase 3 design calls for N=160, 3:1 randomization, 26-week placebo-controlled period, primary composite responder endpoint at Week 26.
• Obesity candidate MBX 4291 targets once-monthly dosing; 12-week Phase 1 MAD results guided to Q4 2026.
• Cash, cash equivalents, marketable securities totaled USD 418.6 million as of June 30, 2026; runway projected into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.